Allscripts (MDRX) Gets a Hold Rating from Cantor Fitzgerald


In a report released yesterday, Steven Halper from Cantor Fitzgerald reiterated a Hold rating on Allscripts (MDRX), with a price target of $10. The company’s shares closed yesterday at $9.94.

Halper commented:

“. We reiterate our Neutral rating on MDRX shares and maintain our price target at $10, After the market close on Thursday, May 2, MDRX reported 1Q19 results, with revenue slightly below our estimate. 1Q19 bookings increased 9% y/y. MDRX reiterated its 2019 guidance for non-GAAP EPS and bookings. The company continues its policy of not providing full year revenue guidance, but provided 2Q19 revenue guidance, which was below our estimate but in line with FactSet consensus. We note the company had previously provided a modest three-year CAGR outlook.”

According to TipRanks.com, Halper is a 5-star analyst with an average return of 16.3% and a 61.3% success rate. Halper covers the Services sector, focusing on stocks such as WellCare Health Plans, Tivity Health Inc, and Hms Holdings Corp.

Allscripts has an analyst consensus of Hold, with a price target consensus of $11.60.

See today’s analyst top recommended stocks >>

The company has a one-year high of $14.97 and a one-year low of $8.54. Currently, Allscripts has an average volume of 2.14M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Allscripts Healthcare Solutions, Inc. engages in the provision of clinical, financial, connectivity, information solutions, and related professional services. It operates through the following segments: Clinical and Financial Solutions; Population Health; and Netsmart.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts